Brett Davis’ Post

View profile for Brett Davis, graphic

Chief Innovation Officer @ Deloitte Consulting LLP | General Manager, Converge by Deloitte

It has never been a more exciting time to be in life sciences. The convergence of scientific advancements with amazing progress in cloud, AI and data science is poised to make personalized medicine an affordable reality for the masses. No where is this more evident than in how biopharmaceutical companies can manage end to end evidence across the drug discovery lifecycle including real-world evidence (RWE).   At Deloitte, we’ve been building and innovating on enterprise RWE platforms for a while - in fact we launched ConvergeHEALTH by Deloitte ten years ago with the explicit goal to accelerate value based, personalized healthcare through cloud native analytics platforms to make sense of the ‘digital exhaust’ of the healthcare system. And our platforms are supporting many of the worlds leading biopharma to do just that… But now its time for an upgrade and there is a real opportunity to modernize and implement next generation platforms to take advantage of the AI moment we find ourselves in and finally break down the siloes across the multiple evidence modalities that exist today.   My colleague and friend Jeffrey Morgan (who joined Deloitte over 10 years ago), who leads our Real-World Evidence Practice, is hosting a forward-facing conversation on June 5 about industrializing an enterprise real-world evidence capability.   He’ll be joined by two leaders in this work -- Anu Sharma, Director and Principal Scientist at Merck, and Jennifer Webster, VP of RWE Platforms & Partnerships at Pfizer to discuss how they are harnessing RWE in their everyday and the future trends they’re seeing.    Register today for the upcoming debrief by clicking here (https://deloi.tt/3yBww5s) and I look forward to learning alongside you! 

  • No alternative text description for this image
Kwame Som-Pimpong

Building businesses in the energy, natural resources, and industrials sectors

1mo
Like
Reply

To view or add a comment, sign in

Explore topics